[QALYS or not QALYS: that is the question?]
- PMID: 8552855
[QALYS or not QALYS: that is the question?]
Abstract
The article discusses the proposal of some health economists to use the "cost per QALY (quality-adjusted-life year)" ratio as an universal indicator for economic assessment of medical interventions, in the so-called "cost-utility" analyses. Authors argue that QALYs are not a straightforward application of expected utility theory, which is the standard economic model of individual behaviours toward risk and uncertainty. Indeed, QALYs are compatible with economic utility theory only if individuals' preferences regarding health states satisfy certain very restrictive properties: utility independence between length of life and quality of life, constancy of the proportional trade-off between quality of life and length of life, risk neutrality towards health states, constancy through time of the utility associated with each health state. Aggregation of individual QALYs to obtain an indicator for patient groups at the societal level also raises complex equity problems. Last but not least, from the epistemological point of view, QALYs are based on the hypothesis that health interventions only affect the health of the individual and not any other aspects of his well-being. The authors conclude that the "cost per QALY" approach should be abandoned in order to avoid ambiguities that could impede the development of health economics in the medical field.
Similar articles
-
Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.Pediatrics. 2005 May;115(5):e600-14. doi: 10.1542/peds.2004-2127. Pediatrics. 2005. PMID: 15867026 Review.
-
A new and more robust test of QALYs.J Health Econ. 2004 Mar;23(2):353-67. doi: 10.1016/j.jhealeco.2003.11.004. J Health Econ. 2004. PMID: 15019761
-
Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?Eur J Cardiovasc Prev Rehabil. 2008 Oct;15(5):608-15. doi: 10.1097/HJR.0b013e328304fec1. Eur J Cardiovasc Prev Rehabil. 2008. PMID: 18800005 Clinical Trial.
-
Cost-utility analysis of cataract surgery in the second eye.Ophthalmology. 2003 Dec;110(12):2310-7. doi: 10.1016/S0161-6420(03)00796-6. Ophthalmology. 2003. PMID: 14644712
-
Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.Health Econ. 2004 Dec;13(12):1203-10. doi: 10.1002/hec.901. Health Econ. 2004. PMID: 15386669 Review.
Cited by
-
The Great I-QALY Disaster.Innov Pharm. 2020 Jul 31;11(3):10.24926/iip.v11i3.3359. doi: 10.24926/iip.v11i3.3359. eCollection 2020. Innov Pharm. 2020. PMID: 34007635 Free PMC article.